Reassessing the reassessment of suPAR in glomerular disease

Frontiers in Medicine

Volumn 2, Issue JAN, 2015, Pages

  Meijers, Björn K I ^a,b   Reiser, Jochen ^c  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

FSGS; GFR; Glomerular disease; Mouse models; suPAR

Indexed keywords

EID: 85061981968     PISSN: None     EISSN: 2296858X     Source Type: Journal    
DOI: 10.3389/fmed.2014.00059     Document Type: Note

References (5)

1. Wei C, El HS, Li J, Fornoni A, Goes N, Sageshima J, et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med (2011) 17:952-60. doi: 10.1038/nm.2411
2. Spinale J, Mariani L, Kapoor S, Zhang J, Weyant R, Song P, et al. A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease. Kidney Int (2014). doi:10.1038/ki.2014.346
3. Meijers B, Maas RJ, Sprangers B, Claes K, Poesen R, Bammens B, et al. The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis. Kidney Int (2014) 85:636-40. doi:10.1038/ki.2013.505
4. Meijers B, Poesen R, Claes K, Dietrich R, Bammens B, Sprangers B, et al. Soluble urokinase receptor is a biomarker of cardiovascular disease in chronic kidney disease. Kidney Int (2015) 87:210-6. doi:10.1038/ki.2014.197
5. Li F, Zheng C, Zhong Y, Zeng C, Xu F, Jiang Q, et al. Relationship between serum soluble urokinase plasminogen activator receptor level and steroid responsiveness in FSGS. Clin J Am Soc Nephrol (2014) 9(11):1903-11. doi:10.2215/CJN.02370314